Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
Provided By GlobeNewswire
Last update: Jun 5, 2025
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –
– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –
– Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today–
